Sangamo Therapeutics Inc (NASDAQ:SGMO) Expected to Post Quarterly Sales of $17.03 Million

Equities research analysts expect Sangamo Therapeutics Inc (NASDAQ:SGMO) to announce $17.03 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Sangamo Therapeutics’ earnings, with the highest sales estimate coming in at $22.60 million and the lowest estimate coming in at $4.42 million. Sangamo Therapeutics reported sales of $26.84 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 36.5%. The company is scheduled to announce its next earnings report on Thursday, February 27th.

On average, analysts expect that Sangamo Therapeutics will report full-year sales of $64.62 million for the current fiscal year, with estimates ranging from $52.00 million to $70.20 million. For the next financial year, analysts expect that the company will post sales of $111.07 million, with estimates ranging from $55.10 million to $240.50 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.10. Sangamo Therapeutics had a negative return on equity of 30.33% and a negative net margin of 159.12%. The firm had revenue of $21.96 million for the quarter, compared to analyst estimates of $12.16 million. During the same period in the previous year, the company posted ($0.13) earnings per share. The business’s revenue was down 6.8% on a year-over-year basis.

SGMO has been the topic of several recent research reports. Zacks Investment Research cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 16th. HC Wainwright started coverage on shares of Sangamo Therapeutics in a research report on Monday, August 26th. They issued a “buy” rating and a $16.00 target price for the company. Wedbush reissued a “hold” rating and issued a $11.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, November 12th. Finally, BidaskClub raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 28th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $13.50.

NASDAQ SGMO traded up $0.06 during mid-day trading on Monday, hitting $11.66. The stock had a trading volume of 1,948,555 shares, compared to its average volume of 1,772,521. The firm’s 50 day moving average is $9.68 and its 200 day moving average is $10.25. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.77 and a quick ratio of 4.77. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -16.66 and a beta of 2.84. Sangamo Therapeutics has a twelve month low of $6.26 and a twelve month high of $13.91.

Several hedge funds have recently bought and sold shares of SGMO. First Manhattan Co. purchased a new position in Sangamo Therapeutics during the second quarter worth approximately $32,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of Sangamo Therapeutics in the 2nd quarter worth $50,000. Tiverton Asset Management LLC purchased a new position in shares of Sangamo Therapeutics during the 2nd quarter worth $79,000. Tower Research Capital LLC TRC raised its holdings in shares of Sangamo Therapeutics by 1,621.1% during the 3rd quarter. Tower Research Capital LLC TRC now owns 11,170 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 10,521 shares during the period. Finally, McGuire Investment Group LLC acquired a new position in shares of Sangamo Therapeutics during the 3rd quarter valued at about $110,000. Institutional investors and hedge funds own 70.78% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Featured Story: Should You Consider an Index Fund?

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with's FREE daily email newsletter.